278 related articles for article (PubMed ID: 9428497)
1. Taurine attenuates recombinant interleukin-2-activated, lymphocyte-mediated endothelial cell injury.
Finnegan NM; Redmond HP; Bouchier-Hayes DJ
Cancer; 1998 Jan; 82(1):186-99. PubMed ID: 9428497
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
Ozdemir O; Ravindranath Y; Savaşan S
J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
[TBL] [Abstract][Full Text] [Related]
3. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
4. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
Mulé JJ; Krosnick JA; Rosenberg SA
J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
[TBL] [Abstract][Full Text] [Related]
6. Modulation of natural and interleukin-2-induced tumour-cytolytic activities by the members of a protein family related to beta-thromboglobulin.
Klein-Struckmeier A; Knüver-Hopf J; Mohr H
Cancer Immunol Immunother; 1991; 34(3):175-80. PubMed ID: 1836749
[TBL] [Abstract][Full Text] [Related]
7. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
8. The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity.
Voshol H; Dullens HF; Den Otter W; Vliegenthart JF
Anticancer Res; 1996; 16(1):155-9. PubMed ID: 8615602
[TBL] [Abstract][Full Text] [Related]
9. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
[TBL] [Abstract][Full Text] [Related]
10. Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.
Dullens HF; Wind JC; Maas RA; Bernsen MR; Vulto IM; Rademakers LH; Den Otter W
Int Immunol; 1991 Oct; 3(10):959-64. PubMed ID: 1756146
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine kinase inhibition blocks granule exocytosis and cytolytic function of lymphokine-activated killer cells.
Frederick MJ; Yu TK; Krohn EG; Johnston DA; Grimm EA
Immunopharmacology; 1996 Nov; 35(2):83-102. PubMed ID: 8956972
[TBL] [Abstract][Full Text] [Related]
12. Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines.
Wang MH; Flad HD; Böhle A; Chen YQ; Ulmer AJ
Immunol Lett; 1991 Mar; 27(3):191-7. PubMed ID: 2060970
[TBL] [Abstract][Full Text] [Related]
13. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
14. Signal transduction via phosphorylated adhesion molecule, LFA-1 beta (CD18), is increased by culture of natural killer cells with IL-2 in the generation of lymphokine-activated killer cells.
Umehara H; Takashima A; Minami Y; Bloom ET
Int Immunol; 1993 Jan; 5(1):19-27. PubMed ID: 8095153
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
[TBL] [Abstract][Full Text] [Related]
18. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
[TBL] [Abstract][Full Text] [Related]
19. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors.
Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G
Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961
[TBL] [Abstract][Full Text] [Related]
20. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]